Alector, Alzheimer's disease

UPDATED: Alector lays off 17% of staff after AbbVie-partnered Alzheimer's asset fails phase 2
Alector’s AbbVie-partnered Alzheimer's disease asset has failed to slow disease progression in a phase 2 study, the latest in a string of investigational meds missing the mark in the indication.
Alector’s AbbVie-Partnered Alzheimer’s Program Fails Phase II, Triggering a 17% Layoff
Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech expects its current cash position to last it through 2026.
Alector: Bleak Prospects After Alzheimer's Failure
Alector has significant cash reserves but faces high cash burn, with no immediate catalysts and uncertain prospects for its remaining pipeline. Learn more on ALEC stock here.
Alector AL002 INVOKE-2 Phase II Alzheimer’s trial misses goal
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD).
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce
Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is cut by 17%.
Alector Therapeutics’ novel Alzheimer’s strategy fails in Phase 2 trial
Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's disease. Its drug failed the Phase 2 trial.
Alector stock drops after Alzheimer’s drug fails in Phase II trial
"Alector stock drops after Alzheimer’s drug fails in Phase II trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
Alector turns to layoffs as Alzheimer’s drug fails
The brain drug developer is letting go of around 41 of its 238 employees, in a move the company says will help “align resources” with its strategic priorities.
Alector, Inc.: Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment
Alector Plummets After Alzheimer's Drug Trial Fails Primary Endpoint
Alector said that, in addition to failure to meet the primary endpoint of the study, no treatment effects favored AL002 on secondary clinical and functional endpoints. The company said it had $457.2 million worth of cash,
Buy Rating Maintained for Alector Despite AL002 Setback, Focus on Promising AL001 and Strong Financials
Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on ALEC stock, giving a Buy rating today.Don't Miss our Black ...
Morningstar3d
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update
The instances of ARIA were primarily seen in participants treated with AL002. “We, at Alector, recognize the importance of advancing therapeutics to treat Alzheimer’s disease and remain ...